This company listing is no longer active
Instituto Hermes Pardini Past Earnings Performance
Past criteria checks 2/6
Key information
11.4%
Earnings growth rate
12.2%
EPS growth rate
Healthcare Industry Growth | 11.6% |
Revenue growth rate | 14.8% |
Return on equity | 17.6% |
Net Margin | 8.2% |
Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Why We Like The Returns At Instituto Hermes Pardini (BVMF:PARD3)
Jul 01What Does Instituto Hermes Pardini S.A.'s (BVMF:PARD3) Share Price Indicate?
Jun 10We Think Instituto Hermes Pardini's (BVMF:PARD3) Profit Is Only A Baseline For What They Can Achieve
Feb 17At R$22.16, Is It Time To Put Instituto Hermes Pardini S.A. (BVMF:PARD3) On Your Watch List?
Jan 31Does Instituto Hermes Pardini (BVMF:PARD3) Have A Healthy Balance Sheet?
Aug 19Is Now An Opportune Moment To Examine Instituto Hermes Pardini S.A. (BVMF:PARD3)?
Jun 08Should You Be Adding Instituto Hermes Pardini (BVMF:PARD3) To Your Watchlist Today?
May 22Here's What You Should Know About Instituto Hermes Pardini S.A.'s (BVMF:PARD3) 1.3% Dividend Yield
Apr 19The Returns On Capital At Instituto Hermes Pardini (BVMF:PARD3) Don't Inspire Confidence
Apr 02Instituto Hermes Pardini (BVMF:PARD3) Has A Pretty Healthy Balance Sheet
Mar 16Is Instituto Hermes Pardini S.A.'s (BVMF:PARD3) Recent Performance Tethered To Its Attractive Financial Prospects?
Feb 08Would Shareholders Who Purchased Instituto Hermes Pardini's (BVMF:PARD3) Stock Three Years Be Happy With The Share price Today?
Jan 19We're Watching These Trends At Instituto Hermes Pardini (BVMF:PARD3)
Dec 28We Think Instituto Hermes Pardini (BVMF:PARD3) Can Stay On Top Of Its Debt
Dec 10Instituto Hermes Pardini S.A. Just Beat Revenue By 6.5%: Here's What Analysts Think Will Happen Next
Nov 21Our Take On The Returns On Capital At Instituto Hermes Pardini (BVMF:PARD3)
Sep 12Does Instituto Hermes Pardini (BVMF:PARD3) Have A Healthy Balance Sheet?
Aug 25Investor Optimism Abounds Instituto Hermes Pardini S.A. (BVMF:PARD3) But Growth Is Lacking
Aug 07At R$28.99, Is It Time To Put Instituto Hermes Pardini S.A. (BVMF:PARD3) On Your Watch List?
Aug 06New Forecasts: Here's What Analysts Think The Future Holds For Instituto Hermes Pardini S.A. (BVMF:PARD3)
Jul 24Is Now The Time To Put Instituto Hermes Pardini (BVMF:PARD3) On Your Watchlist?
Jul 12Instituto Hermes Pardini S.A. (BVMF:PARD3) Vies For A Place In Your Dividend Portfolio: Here's Why
Jun 29Revenue & Expenses Breakdown
How Instituto Hermes Pardini makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 22 | 2,099 | 173 | 242 | 0 |
30 Sep 22 | 2,069 | 171 | 245 | 0 |
30 Jun 22 | 2,050 | 194 | 244 | 0 |
31 Mar 22 | 2,051 | 227 | 242 | 0 |
31 Dec 21 | 1,986 | 214 | 237 | 0 |
30 Sep 21 | 1,986 | 217 | 225 | 0 |
30 Jun 21 | 1,927 | 225 | 202 | 0 |
31 Mar 21 | 1,663 | 161 | 183 | 0 |
31 Dec 20 | 1,494 | 127 | 180 | 0 |
30 Sep 20 | 1,342 | 127 | 173 | 0 |
30 Jun 20 | 1,240 | 110 | 175 | 0 |
31 Mar 20 | 1,326 | 145 | 180 | 0 |
31 Dec 19 | 1,354 | 158 | 179 | 0 |
30 Sep 19 | 1,321 | 140 | 182 | 0 |
30 Jun 19 | 1,291 | 131 | 181 | 0 |
31 Mar 19 | 1,248 | 123 | 183 | 0 |
31 Dec 18 | 1,205 | 123 | 177 | 0 |
30 Sep 18 | 1,182 | 126 | 184 | 0 |
30 Jun 18 | 1,156 | 129 | 164 | 0 |
31 Mar 18 | 1,142 | 128 | 159 | 0 |
31 Dec 17 | 1,117 | 130 | 152 | 0 |
30 Sep 17 | 1,069 | 120 | 132 | 0 |
30 Jun 17 | 1,013 | 114 | 135 | 0 |
31 Mar 17 | 957 | 113 | 126 | 0 |
31 Dec 16 | 899 | 103 | 119 | 0 |
30 Sep 16 | 868 | 96 | 126 | 0 |
30 Jun 16 | 839 | 85 | 117 | 0 |
Quality Earnings: PARD3 has high quality earnings.
Growing Profit Margin: PARD3's current net profit margins (8.2%) are lower than last year (10.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PARD3's earnings have grown by 11.4% per year over the past 5 years.
Accelerating Growth: PARD3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PARD3 had negative earnings growth (-19.2%) over the past year, making it difficult to compare to the Healthcare industry average (-21.6%).
Return on Equity
High ROE: PARD3's Return on Equity (17.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/04/29 23:52 |
End of Day Share Price | 2023/04/28 00:00 |
Earnings | 2022/12/31 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Instituto Hermes Pardini S.A. is covered by 4 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Pedro Mariani | BofA Global Research |
Gustavo Miele | Goldman Sachs |
Santhosh Seshadri | HSBC |